Anti-Tumor Effects of Semaphorin 4D Blockade Unravel a Novel Pro-Invasive Mechanism of Vascular Targeting Agents Abstract #2742

Introduction: One of the main consequences of inhibition of neovessel growth produced by angiogenesis inhibitors is increased intratumor hypoxia. Growing evidence indicates that tumor cells escape from this hypoxic environment to better nourished locations, presenting hypoxia as a positive stimulus for invasion. Particularly, anti-VEGF/R therapies produce hypoxia-induced invasion and metastasis in a spontaneous mouse model of pancreatic neuroendocrine cancer, RIP1-Tag2.
Aim(s): In search for alternative angiogenesis targets to be blocked in neuroendocrine tumors (NETs), we focused our attention to Semaphorin 4D (Sema4D) as a well-established pro-angiogenic molecule.
Materials and methods: A novel vascular targeting agent blocking Sema4D (Mab67 anti-Sema4D Ab, Vaccinex Inc.) was used to treat RIP1-Tag2 NETs transgenic mice at 1mg/animal/week.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: PhD Oriol Casanovas

To read results and conclusion, please login ...

Further abstracts you may be interested in

#603 Role of Semaphorins and Their Signaling Pathway in the Progression of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Introduction: Semaphorin family, a part of axon guidance molecules, is involved in many types of epithelial cancers. However, little is known about its potential function in GEP-NETs.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Colette Roche
#1734 Efficacy of Lanreotide (LAN), Both Alone and in Combination with Targeted Therapies in a Preclinical Model of Pancreatic Neuroendocrine Tumors (pNETs)
Introduction: CLARINET trial has proven the antiproliferative effects of LAN in patients with non-functioning gastro-entero-pNETs. However, the combination of LAN with targeted therapies is widely used in clinical practice and should be further evaluated.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: PhD Oriol Casanovas
Keywords: Lanreotide, pNET
#1539 Slit-Robo Signaling Links to Ras Activity to Suppress Metastasis and Is Associated with Time-to-Progression in Pancreatic Neuroendocrine Tumors
Introduction: mRNA signatures of distinct metastatic phenotypes of pancreatic NETs (pNETs) exhibit differences in several components of the Slit-Robo axon guidance system.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: PD Dr. med. Christian Fischer
#1637 The Effect of the Autophagy Inhibitor Chloroquine (CQ), Alone or in Combination with mTOR Inhibitors, on Neuroendocrine Tumor (NET) Growth and Metastatic Spread in Mouse Models
Introduction: mTOR inhibitors (mTORi) such as RAD001 demonstrated promising anti-cancer effect in NETs. Autophagy, a cell survival mechanism, is activated by mTORi. We have recently shown in the human NET cell line BON1 that autophagy is essential for cell survival. Treatment with CQ alone or together with mTORi robustly inhibited cell proliferation and survival, suggesting that treatment with CQ may potentiate the anti-tumorigenic effects of mTORi.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: MD Simona Grozinsky-Glasberg
Keywords: autophagy, mTORi, NET
#1293 The Role of Hepatic Intra-arterial Therapies in Metastatic Neuroendocrine Tumours (NETs): A Specialist Center Experience.
Introduction: Liver metastases are relatively common in patients with NETs, having a negative impact on prognosis. The options for selective liver metastases therapy are limited to catheter guided procedures: TACE, TAE or SIRT. Data regarding the effectiveness & safety of these procedures in different types of NETs is limited.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Others
Presenting Author: MD Simona Glasberg